C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact
Source: SeekingAlpha
2026-03-10 07:49:49 ET
Thesis
Read the full article on Seeking Alpha
For further details see:
C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact
C4 Therapeutics Inc.
NASDAQ: CCCC
CCCC Trading
-2.11% G/L:
$2.785 Last:
1,197,466 Volume:
$2.78 Open:
CCCC Latest News
March 05, 2026 09:00:00 am
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
February 26, 2026 07:00:00 am
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
CCCC Stock Data
$276,378,373
60,917,496
0.2%
27
N/A
Biotechnology & Life Sciences
Healthcare
US
Watertown
